Clinical TrialJul 30, 2026, 04:08 PM
Keros Therapeutics Receives $20M Milestone for Elritercept
AI Summary
Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from its partner Takeda Pharmaceuticals U.S.A., Inc. This payment follows the dosing of the first patient in the ELRiSE MDS clinical trial, a Phase 3 study evaluating elritercept for the treatment of anemia due to myelodysplastic syndromes. Keros plans to distribute 25% of the net cash proceeds from this milestone to its stockholders. The company previously received a $200 million upfront payment in February 2025 and is eligible for over $1.1 billion in potential future milestones under the license agreement.
Key Highlights
- Keros Therapeutics to receive a $20 million development milestone payment.
- Payment from partner Takeda Pharmaceuticals U.S.A., Inc. for elritercept.
- Milestone triggered by dosing of first patient in ELRiSE MDS Phase 3 clinical trial.
- ELRiSE MDS trial evaluates elritercept for anemia in myelodysplastic syndromes (MDS).
- Keros expects to distribute 25% of net cash proceeds from this payment to stockholders.
- Previously received a $200 million upfront payment in February 2025.
- Eligible for potential future development, commercial, and sales milestones exceeding $1.1 billion.
Price Impact
More from KROS